Searchable abstracts of presentations at key conferences in endocrinology

ea0090p770 | Thyroid | ECE2023

Does targeting a TSH ≤ 2.5 mmol/l improve fertility in euthyroid women?

Nasri Ismail

Introduction: hypothyroidism is among the most frequent causes of infertility, our objective is to analyze this population in order to evaluate the effectiveness of treatment with levothyroxine.Patients and methods: this is a retrospective interventional study from September 2017 to September 2022.Inclusion criteria: infertility, TSH>2.5 mmol/lExclusion criteria: infertility for less than 1 year, age ≥ ...

ea0090ep526 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

GAZA study (Glycémie Améliorée Zéro Antidiabétique), a new antidiabetic therapeutic approach without pharmacoligical treatment

Nasri Ismail

Introduction: In diabetology all the recommendations insist on the intensification of the antidiabetic treatment with the maintenance of the same treatment if the type 2 diabetes mellitus is balanced. Our work insists on dietary treatment and focuses on weight loss in order to degress antidiabetic treatment until cessation.Patients and methods: This is a prospective interventional study. Type 2 diabetes mellitus on pharmacological treatment: treatment is...

ea0090ep527 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Diabetes and Ramadan, special Ramadan blood glucose self-monitoring table

Nasri Ismail

Background: International Diabetes Federation (IDF), in collaboration with the Diabetes and Ramadan (DAR) International Alliance proposed in 2021, IDF-DAR Practical Guidelines with a score that allows certain patients even on insulin to fast which requires regular and appropriate blood glucose monitoring.Aim: Develop a special Ramadan blood glucose self-monitoring table in order to limit the risk of acute compilations during this month.<p class="abst...

ea0063p137 | Diabetes, Obesity and Metabolism 1 | ECE2019

The EMPA-REG OUTCOME, a real cardiovascular benefit or a play on words?

Nasri Ismail

Introduction: The EMPA-REG OUTCOME is a cardiovascular safety study with empaglifozin that has shown a reduction in cardiovascular mortality and a decrease in hospitalization for heart failure. Our work is based on the analysis of the protocol that recognized five changes, the last, 3 years after the start of the study and which affects the definitions of the elements of the primary composite, and following these modifications, we find that the mortality Cardiovascular was inc...